Occupational Exposure to Solar UVR Linked to Nonmelanoma Skin Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 20, 2023 -- Occupational exposure to solar ultraviolet radiation (UVR) is associated with a substantial burden of nonmelanoma skin cancer (NMSC), according to a study published in the November issue of Environment International.
Frank Pega, from the World Health Organization in Geneva, and colleagues presented WHO and International Labour Organization (ILO) estimates of global, regional, national, and subnational occupational exposures to UVR for 195 countries/regions and the global, regional, and national attributable burdens of NMSC for 183 countries for 2000, 2010, and 2019. Using 166 million observations from 763 cross-sectional surveys for 96 countries/areas, occupational exposure to UVR was modeled via proxy of occupation with outdoor work. By applying population-attributable fractions (PAFs) from estimates of the population occupationally exposed to UVR and the risk ratio for NMSC, the attributable NMSC burden was estimated.
The researchers found that in 2019, 1.6 billion workers were occupationally exposed to UVR globally, representing 28.4 percent of the working-age population. The PAFs for NMSC deaths and disability-adjusted life years (DALYs) were 29.0 and 30.4 percent, respectively; attributable burdens were 18,960 deaths and 0.5 million DALYs. A larger burden was seen for men and older age groups. Attributable deaths and DALYs almost doubled during 2000 to 2019.
"WHO and the ILO estimate that occupational exposure to UVR is common and leads to substantial numbers of deaths and of DALYs from NMSC," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Non-Hispanic Black Melanoma Patients Present With Advanced Disease
WEDNESDAY, May 15, 2024 -- Non-Hispanic Black (NHB) melanoma patients have distinct tumor characteristics, presenting with more advanced disease and exhibiting worse outcomes...
Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs...
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.